Skip to content

Application of Huaxi Zhu's parathyroid typing and parathyroid autotransplantation in reducing postoperative hypoparathyroidism

Application of Huaxi Zhu's parathyroid typing and parathyroid autotransplantation in reducing postoperative hypoparathyroidism

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900023654
Enrollment
Unknown
Registered
2019-06-05
Start date
2019-06-03
Completion date
Unknown
Last updated
2019-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypoparathyroidism

Interventions

experimental group :using huaxi zhu's parathyroid gland typing
control group:using huaxi zhu's parathyroid gland typing

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. patients aged from 18 to 70 years who were diagnosed with PTC by preoperative fine needle cytology or histology examination; 2. indications for total thyroidectomy: the 2012 guidelines for diagnosis and treatment of thyroid nodule and differentiated thyroid cancer (Chinese version) shall govern: (1) Bilateral cancer lesions; (2) highly invasive subtypes, such as: high cell type of PTC, columnar cell type, diffuse sclerosis type, solid subtype; (3) local and distant metastasis has occurred, and 131I postoperative treatment is needed; (4) accompanied by extra-glandular invasion (such as subcutaneous adipose tissue, muscle, trachea, esophagus, carotid artery or mediastinal invasion, etc.); (5) the maximum diameter of the original oven is >1cm; 6 have thyroid cancer risk factors; PTC; Accompanied by contralateral thyroid nodules; 9 (9 BRAF) mutation positive patients; 3. indications for unilateral central region lymph node dissection: all PTC patients routinely underwent central region lymph node dissection on the affected side; 4. the indications for bilateral central lymph node dissection are in accordance with any of the following: (1) T3, T4 tumor; (2) cervical lymph node metastasis; (3) highly invasive subtypes; (4) anterior laryngeal and tracheal lymph node metastasis; 6 imaging or intraoperative findings of contralateral central lymph node enlargement; PTC; The maximum diameter of the tumor is >1cm. 9 (9 BRAF mutation positive patients; Patients have a strong desire to be more thorough; 5. before enrollment, the results of laboratory examination were in line with the operation conditions, and there were no contraindications; 6. volunteer to participate, sign informed consent, and be willing to follow up for a long time.

Exclusion criteria

Exclusion criteria: 1) preoperative fine needle puncture indicates non-ptc or suspicious PTC patients; 2) preoperative examination revealed abnormal PTH and serum calcium; 3) pregnant and lactating women (female patients were routinely excluded from urine pregnancy test); 4) previous allergy to research drugs; 5) unable to tolerate surgery for various reasons; 6) the researcher thinks that the group is not suitable for inclusion; 7) poor compliance of subjects, unwilling to participate; 8) With psychological, family, social or geographical constraints that may affect program compliance and follow-up time.

Design outcomes

Primary

MeasureTime frame
PTH;blood calcium;blood magnesium;serum phosphate;blood vitamin D;

Countries

China

Contacts

Public ContactSu Anping

Department of Thyroid Surgery, West China Hospital, Sichuan University

suanpingping@126.com+86 15881104970

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026